AstraZeneca: antibody Imfinzi fails lung cancer study
(CercleFinance.com) - AstraZeneca said on Tuesday that a Phase III trial on its Imfinzi antibody in patients with non-small cell lung cancer who have received at least two prior treatments did not meet the primary endpoints of a statistically-significant and clinically-meaningful improvement in progression-free survival and overall survival.
Analysts believe that this news will only have a minimal impact on the share: Paris-based broker Oddo says that the indication targeted by this study only had a "limited impact" commercially.
Indeed, the trial was aimed at patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two previous treatments.
The London-listed shares of AstraZeneca were down 1% in early-morning trading today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Analysts believe that this news will only have a minimal impact on the share: Paris-based broker Oddo says that the indication targeted by this study only had a "limited impact" commercially.
Indeed, the trial was aimed at patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two previous treatments.
The London-listed shares of AstraZeneca were down 1% in early-morning trading today.
Copyright (c) 2018 CercleFinance.com. All rights reserved.